A Theoretical Framework for Ligand-Functionalised Magnetic Lipid Nanoparticles in Glioblastoma Therapy.

Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumour with limited treatment options and a poor prognosis. Therapeutic failure is driven by multiple barriers, including the blood-brain barrier (BBB), the tumour microenvironment (TME), and intratumoural heterogeneity. Conventional delivery systems often fail to achieve sufficient drug accumulation or controlled release within the tumour. In this review, we outline a theoretical framework for the design of ligand-functionalised magnetic lipid nanoparticles (MF-R-LNs), a multifunctional nanoplatform that integrates active targeting, stimuli-responsive drug release, and external magnetic-field control. The proposed MF-R-LNs incorporate superparamagnetic iron oxide nanoparticles (SPIONs) for magnetic guidance and hyperthermia; polyethylene glycol (PEG) for extended circulation; and surface ligands such as peptides, antibodies, or aptamers to target GBM-specific receptors including epidermal growth factor receptor (EGFR), Interleukin-13 receptor alpha-2 (IL-13Rα2), and integrins. Triggered release mechanisms such as pH-sensitive lipids, redox cleavable linkers, and enzyme-responsive coatings enable selective drug release within the TME. Magnetic hyperthermia serves as both a therapeutic modality and a remote trigger to enhance release and tumour penetration. This modular design offers a theoretically robust strategy to overcome the key physiological and therapeutic barriers in GBM. We discuss the rationale behind each design feature, explore potential synergies, and highlight translational challenges such as tumour heterogeneity, manufacturing complexity, and safety concerns. Despite encouraging preclinical evidence, clinical translation faces substantial hurdles, notably patient-specific heterogeneity and scalable GMP manufacturing/characterisation of multi-component nanoplatforms. While preclinical validation remains necessary, this framework may inform future efforts to develop spatiotemporally controlled, multifunctional therapeutics for glioblastoma. This manuscript is a conceptual framework review that synthesises current strategies into actionable guidance for designing and reporting MF-R-LNs for GBM.